ClinicalTrials.gg
RecruitingNCT07442851Updated May 7, 2026

SickleFit Exercise and Nutrition Study

An interventional study of SickleFit Exercise plus Nutrition in Sickle Cell Disease and Aging, sponsored by Duke University. Recruiting at 1 site in United States. Open to participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2026-05-07.

Sponsored by Duke University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
35 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Anemia, Sickle Cell by Duke University — 2 open to participants now, 2 under way, none of them phase 3. Anemia, Sickle Cell · Duke University.

Planned enrollment
10th of 19
40 · median 40
Started
2026
the only one that year
No phase
14 of 25
2 open now
Registered
25th of 25
by date

Among the 25 studies in Anemia, Sickle Cell by Duke University, this one is the 10th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2026, is one of 14 with no phase, and was the 25th registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

2 of the 25 studies in Anemia, Sickle Cell by Duke University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 35 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Anemia, Sickle Cell by Duke University, or all of them as a file.
02

Study summary

To goal of this study is to pilot the SickleFit exercise and nutrition intervention in adults with sickle cell disease in a randomized control trial

Read the detailed description

Investigators will pilot the SickleFit personalized exercise plus dietitian-facilitated nutrition intervention randomized control trial in adults (age ≥ 35 years) with sickle cell disease.

03

Conditions studied

  • Sickle Cell Disease
  • Aging

Keywords

  • sickle cell disease
  • exercise
  • nutrition
  • aging
  • functional impairment
04

Who can participate

Ages eligible
35 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Laboratory-confirmed diagnosis of sickle cell disease (any genotype)
  • Understand and speak English by self-report
  • Age ≥ 35 years old

Exclusion criteria

Exclusion Criteria:

  • Oxygen dependence
  • Unstable cardiac disease
  • Wheelchair-bound
  • Diagnosed with severe cognitive impairment based on ICD-10 codes or reported by their outpatient provider
  • Unable to self-consent
  • Severe uncorrected visual or auditory impairment
  • Pregnant
  • Successfully treated with hematopoietic stem cell transplantation or gene therapy for sickle cell disease
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    SickleFit arm

    Participants in SickleFit arm will complete the Sickle Cell Disease Functional Assessment before and after 12 weeks of SickleFit exeercise+Nutrition intervention.

    Behavioral: SickleFit Exercise plus Nutrition

  • No intervention
    Control Arm

    Participants in the control arm will be on a wait list for SickleFit and will continue to receive usual care during that 12-week period. They will complete the Sickle Cell Disease Functional Assessment at baseline and after 12 weeks on the wait list. After their post-assessment, they will have the option to complete 12 weeks of SickleFit exercise+Nutrition intervention.

Interventions

  • BehavioralSickleFit Exercise plus Nutrition

    SickleFit personalized exercise plus dietitian-facilitated nutrition intervention

06

What researchers measure

Primary outcomes

  1. Feasibility of Randomization

    Feasibility of randomization (proportion of participants randomized out of those approached)

    Time frame: From enrollment to the last paticipants randomized over a 2 year period

  2. Safety/Adverse Events

    number of life-threatening adverse events

    Time frame: adverse events will be measured for both arms up to 6 months

  3. Acceptability

    Proportion of participants reporting satisfaction with the program

    Time frame: From enrollment to after completion of the SickleFit Program over 6 months since we will also measure acceptability for control group

  4. Retention in the program

    retention (proportion of the SickleFit and control groups completing follow up assessment)

    Time frame: From the baseline Sickle Cell Disease Functional Assessment to the post-SCD-FA. Over a 30 week period since post assessments will be completed within 3 months of completion of the SickleFit program or control period.

  5. Adherence

    Adherence (proportion attending ≥ 50% of classes) in the SickleFit arm

    Time frame: From the start of the first SickleFit session to the end of the SickleFit program at 12 weeks

Other outcomes

  1. Performance on the Sickle Cell Disease Functional Assessment (SCD-FA)

    Change in physical performance and patient-reported outcomes on the Sickle Cell Disease Functional Assessment (SCD-FA)

    Time frame: From baseline assessment to completion of the post-assessment within 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Charity I Oyedeji, Teagan Callaway, Rania Mohamed, Reena Ravi, Richard Faldowski, Corey Vessels, Miriam C Morey, John J Strouse; The Sicklefit Exercise Program for Older Adults with Sickle Cell Disease: Feasibility, Acceptability, and Safety. Blood 2024; 144 (Supplement 1): 604. doi: https://doi.org/10.1182/blood-2024-212100

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jan 2028, 21 months after the start.

Of 165 non-industry interventional studies with no phase under Anemia, Sickle Cell, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 54. This study's planned 21 months is below that.

Counting every sponsor, half of 173 studies reached it within 28 months; a quarter within 15 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2026
First posted
Mar 2, 2026
StartActual
Apr 8, 2026
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2028
Last update
May 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07442851
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Mar 2, 2026
Start date
Apr 8, 2026
Primary completion
Jan 2028 (estimated)
Completion
Jan 2028 (estimated)
Last update
May 7, 2026

Study contacts

Teagan Callaway
Contact
SICKLEFIT@duke.edu
919-684-0628
Rania Mohamed
Contact
rania.mohamed@duke.edu
Charity I Oyedeji, MD
principal investigator · Duke University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion